Stockwatch: Almost all roads lead to M&A
This article was originally published in Scrip
Second-quarter earnings season turned on a sixpence last week. After the worries of falling sales, earnings and currencies from the previous two weeks, suddenly the world was a better place with all roads leading to mergers and acquisitions (M&A). Indeed, if you believed all the research published by investment bank analysts last week, all the life science sector's ills can be cured by M&A – although rationally that can't be true since we would eventually end up with only one life science company.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.